UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 28, 2011

AspenBio Pharma, Inc.
(Exact name of registrant as specified in charter)

Colorado | 001-33675 | 84-155338
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (IRS Employer Identification No.)

1585 South Perry Street, Castle Rock, CO | 80104
(Address of principal executive offices) | (Zip Code)

Registrant’s telephone number, including area code (303) 794-2000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.
On October 28, 2011, AspenBio Pharma, Inc. (the “Company”), posted an update presentation on its website. The Company’s presentation is attached to this Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
On October 31, 2011, the Company issued a press release titled — “AspenBio Awarded ISO 13485 Certification.” The press release is filed as Exhibit 99.2 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibits

99.1 | Company Update Presentation, posted to the Company’s website on October 28, 2011.
99.2 | Press release, dated October 31, 2011 issued by AspenBio Pharma, Inc., titled “AspenBio Awarded ISO 13485 Certification.”

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

|  | AspenBio Pharma, Inc. (Registrant)
Date: October 31, 2011 | By: | /s/ Jeffrey G. McGonegal
|  | Name: Jeffrey G. McGonegal
|  | Title: Chief Financial Officer